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Abstract 
Drug interactions with P-glycoprotein (Pgp) were quantitatively assessed using ATPase assay. Two experimental systems 
were used, (i) plasma membranes isolated from a multidrug-resistant cellline, which contained 30% Pgp as fraction of total 
membrane protein, and (ii) purified reconstituted Pgp. The cardioactive drugs verapamil, quinidine, diltiazem, nifedipine, 
and a series of digitalis analogs, interacted irectly with Pgp as shown by effects on ATPase in both systems. Apparent 
affinities of drug binding were calculated. Direct competition was shown between digitoxin and verapamil. Drug-drug 
interaction in vivo at the level of Pgp is expected from the results. This approach seems well-suited for empirical 
determination f drug interactions with Pgp, and prediction of drug-drug interactions. ©1998 Elsevier Science B.V. 
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1. Introduction 
P-glycoprotein (Pgp) is a plasma membrane glyco- 
protein that confers multidrug-resistance (MDR) phe- 
notype by virtue of its ability to exclude a wide range 
of drugs and other hydrophobic ompounds from 
cells in an ATP-dependent manner. Its mechanism of 
action is not yet understood, the most widely-dis- 
cussed current hypothesis that it uses the energy of 
ATP hydrolysis to export drugs from the cell. Mul- 
tidrug-resistance is an important obstacle to success- 
ful chemotherapy of human cancer, thus there is 
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considerable interest in the role of Pgp in this phe- 
nomenon, and in devising methods to circumvent or 
overcome it. Recent reviews of this topic may be 
found in [1-5]. 
Amino acid sequences of Pgp from human and 
rodents have established that it consists of ~ 1280 
residues, predicted to form a tertiary structure that 
may be described schematically as {TMD1-NBS1- 
TMD2-NBS2} where TMD indicates a transmem- 
brane domain of six-helices and NBS indicates a 
cytoplasmic-sided nucleotide binding site. The se- 
quence and predicted structure of Pgp characterize it 
as a prominent member of the family of ABC trans- 
porters [6]. 
Many, diverse compounds that reverse MDR in 
cultured cells have been identified. Called chemosen- 
sitizers or MDR modulators, many are thought o 
either bind directly to Pgp or act as inhibitors of drug 
transport via indirect biophysical effects on plasma 
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membrane fluidity [7]. They include calcium channel 
blockers, calmodulin inhibitors, immunosuppressants, 
steroid hormones, the antiestrogen tamoxifen, and the 
opiate antagonist naloxone [8,9]. As the list of drugs 
which modulate MDR phenotypes continues to ex- 
pand, there has been appreciation of possible interfer- 
ence with physiological function of naturally-ex- 
pressed Pgp. In humans, Pgp is found in secretory 
epithelial tissues, including brush border of renal 
proximal tubules, canalicular membranes in liver, 
apical membranes lining the gut, also the adrenal 
gland, placental trophoblast, and endothelial blood 
barrier in brain and testes [10-12]. This localized 
expression suggested that Pgp may function ormally 
to clear xenobiotics from blood, protect vital organs 
from toxic insult, and transport steroids. Experiments 
with genetically-engineered "knockout" mice have 
supported these ideas [13,14]. Thus, the possibility of 
adverse side-effects of Pgp chemosensitizers is of 
significant concern [14]. 
Several of the drugs that have been discovered to 
be MDR modulators are currently in clinical use. 
Examples are cardioactive drugs that have been used 
for many years to treat angina, arrhythmia, nd con- 
gestive heart failure, including calcium channel 
blockers such as verapamil and diltiazem, anti- 
arrhythmia gents such as quinidine, and cardiac 
glycosides uch as digoxin and digitoxin. It has been 
proposed that some of the complications and adverse 
reactions observed upon administration f these drugs 
[15] may possibly be explained by interactions with 
Pgp, leading to inhibited rug clearance, and exacer- 
bated drug toxicity associated with elevated plasma 
or tissue concentration [ 14,16]. 
Pgp in plasma membranes shows a "basal" rate 
of hydrolysis of MgATP, which is stimulated by 
several fold on addition of drugs, and the turnover 
rate is relatively respectable compared to that of 
ion-transporting ATPases [17-20]. A valuable ap- 
proach to characterize potentially useful chemosensi- 
tizers has been to assay effects on drug-stimulated 
Pgp ATPase activity in plasma membranes i olated 
from cells which overexpress Pgp [21-23]. This ap- 
proach allows the affinity of the chemosensitizer and 
the type of inhibition to be characterized by kinetic 
analysis. In this paper, we first characterize interac- 
tion of a series of cardioactive drugs with Pgp, by 
measuring effects on Pgp ATPase activity in plasma 
membranes which are isolated from a multidrug-re- 
sistant Chinese hamster ovary cell-line and are 
highly-enriched in Pgp. We then extend the approach 
by comparing the results with effects een on ATPase 
activity of purified Pgp reconstituted in liposomes. 
The data allow quantitative assessment of interactions 
of cardioactive drugs with Pgp. We also characterized 
the effects of tamoxifen, progesterone and naloxone 
on Pgp ATPase activity in both plasma membranes 
and purified reconstituted Pgp. 
2. Experimental procedures 
2.1. Preparation of plasma membranes 
Plasma membranes were prepared from the mul- 
tidrug-resistant Chinese hamster ovary cell line 
CR1R12 as in [24,25]. Plasma membranes used in 
this study contained 30% Pgp (w/w) as a fraction of 
total protein, determined as described in [26]. The 
specific Pgp ATPase activity in absence of drug was 
~ 1.25 txmol/min/mg membrane protein. 
2.2. Purification and reconstitution fP-glycoprotein 
Pgp was purified from plasma membranes and 
reconstituted in proteoliposomes a previously de- 
scribed [27], except that the E. coli lipids used 
previously were replaced by a mixture of lipids con- 
sisting of E. coli lipids, L-phosphatidylcholine (egg 
lecithin), phosphatidylserine (bovine brain extract), 
and cholesterol, in a ratio of 60/17.5/10/12.5,  re- 
spectively [28]. The specific activity of pure Pgp was 
3.0 ixmol ATP hydrolyzed/min/mg protein in ab- 
sence of added drug. 
2.3. Assay of ATPase activity 
ATPase activity was assayed at 37°C as described 
in [24]. Briefly, 5 txg of plasma membrane or 0.5 Ixg 
of pure reconstituted Pgp protein in 5 Ixl was added to 
200 Ixl of ATPase assay medium containing 40raM 
Tris-C1, pH 7.4, 0.1 mM EGTA, 15 mM MgSO 4 and 
10mM Tris-ATP [29] at 37°C. 50 ~1 aliquots were 
quenched at appropriate imes in I ml ice-cold 20 mM 
H2SO 4 and Pi was determined [30]. Solutions of drug 
were made freshly from stocks in dimethylsulfoxide 
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(DMSO) with the final concentration of DMSO not 
> 1% (v/v)  in the assay. Linearity of reaction was 
confirmed in all experiments, and ATP hydrolyzed 
was < 10% of total ATP. MgATP concentrations 
were calculated according to [31]. 
2.4. Statistical analysis 
Data from experiments measuring ATP hydrolysis 
vs. [MgATP] or [verapamil] were fit to the 
Michaelis-Menten equation by nonlinear least squares 
regression analysis using Sigma Plot 4.11. All curve 
fits correlated with data with P < 0.05 as deter- 
mined by paired Student's t test. Vma x and K m 
values with standard errors were derived from these 
curves (Table 1) and K~ values were calculated using 
the equation: 
[q 
K i= ( (Kmi /Kmo)  -- 1) " 
For protein assay, proteoliposomes were dilapidated 
by the method of Wessel and Flugge [32]. 
2.6. Materials 
Acetone/ether precipitated E. coli lipids and 
cholesterol were obtained from Avanti Polar Lipids; 
L-phosphatidylcholine from egg yolk and phos- 
phatidylserine from bovine brain extract (Folch frac- 
tion III) were obtained from Sigma. Dye-ligand chro- 
matography reagent Reactive Red 120 agarose Type 
3000-C1, routine chemicals, and drugs, were from 
Sigma. Octylglucoside (OG, n-octyl-o-glucopyrano- 
side) used in the solubilization and purification of 
Pgp was from Calbiochem. 
3. Results 
3.1. P-glycoprotein in plasma membranes and puri- 
fied reconstituted form 
2.5. Routine procedures 
SDS gel electrophoresis and protein assay by 
bicinchoninic acid method in the presence of 1% 
SDS were performed as previously described [24]. 
Table 1 
Characteristics of P-glycoprotein derived from ATPase assay 
Plasma membranes Purified Pgp 
Km(MgATP) (raM) 
no drug 1.4 (0.3) 0.8 (0.11) 
10 ~xM digitoxin 1.9 (0.5) 0.9 (0.15) 
30 IxM digitoxin 1.9 (0.5) 0.7 (0.08) 
Vma x (txmol/min/mg) 
no drug 0.81 (0.06) 3.4 (0.16) 
10 p~M digitoxin 0.67 (0.07) 2.7 (0.16) 
30 p,M digitoxin 0.56 (0.06) 2.0 (0.08) 
Km(verapamil) (txM) 
no drug 0.33 (0.02) 0.4 (0.13) 
3 I, tM digitoxin 0.61 (0.08) 0.7 (0.25) 
10 ~M digitoxin 1.40 (0.35) 1.4 (0.36) 
Vm, x (p~mol/min/mg) 
no drug 2.8 (0.88) 4.9 (0.15) 
3 txM digitoxin 2.6 (0.71 ) 4.4 (0.13) 
10 p~M digitoxin 2.7 (0.56) 4.3 (0.21 )
Ki(digitoxin) (ixM) 3.5 3.5 
The parameters with standard error in parentheses are derived 
from the experiments in Figs. 3 and 4. 
In this work, we used two preparations to assay 
effects of drugs on Pgp ATPase activity. The first 
was a plasma membrane preparation from the mul- 
tidrug-resistant Chinese hamster ovary cell line 
CR 1R 12, which constitutively overexpresses Pgp [24]. 
The plasma membranes contained 30% Pgp as per- 
centage of total membrane protein. Na +, K +-ATPase 
activity could be eliminated either by inclusion of 
ouabain (2raM), or by exclusion of Na + and K + 
from the assay. Here we used the latter approach. The 
ATPase activity of Pgp with ouabain and physio- 
logical concentrations of Na + and K + present in the 
assay medium was not significantly different from 
that measured without Na + and K + (data not shown). 
Ca2+-ATPase, which was very low, was eliminated 
by inclusion of EGTA, and ecto-ATPase and mito- 
chondrial ATPase were absent. The second prepara- 
tion was purified Pgp reconstituted in liposomes. 
During purification of Pgp we substituted here a lipid 
mixture more similar to that of mammalian plasma 
membranes for the E. coli lipids used previously 
[27], to achieve a more native environment. The 
purity of the Pgp was equal to that seen previously 
[27]. Pure Pgp showed no Na +, K+-ATPase activity. 
In both plasma membranes and purified reconstituted 
Pgp, ATPase activity was completely inhibited by 
100 p~M vanadate. 
3.2. Effects of calcium-channel b ockers and quini- 
dine on ATPase activity 
Pgp ATPase activity was stimulated by verapamil, 
diltiazem, nifedipine, and quinidine. Fig. I(A) and 
(B) show the concentration-dependent effects of these 
drugs in plasma membranes and purified reconsti- 
tuted Pgp, respectively. Verapamil and quinidine 
stimulated maximally at 10 IxM, nifedipine at 30 IxM 
and diltiazem at 100 jxM. Concentration required for 
half-maximal stimulation was 1 txM (verapamil, 
quinidine) or 3 IxM (nifedipine, diltiazem). All four 
drugs displayed a biphasic effect; as concentration 
increased beyond that which stimulated maximally, 
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Fig. 2. Effects of cardiac glycosides on ATPase activity of 
P-glycoprotein. (A) Plasma membranes, (B) Purified reconsti- 
tuted Pgp. O, digitoxigenin; *, digoxin; (3, digoxigenin; zx, 
digitoxin; D, ouabain. Each data point represents the mean of at 
least three experiments, _+ SEM. 100% activity in each case 
refers to ATPase measured with no drug addition. 
pamil, quinidine and diltiazem also stimulated AT- 
Pase activity of pure reconstituted Pgp, the effects 
resembling those measured in plasma membranes. 
Results with nifedipine are not included in Fig. I(B), 
since, only one experiment was conducted, but the 
pattern observed was closely similar to that seen in 
Fig. I(A). The data show that these cardioactive 
drugs all interact with Pgp directly, and establish the 
concentrations at which in vivo effects are likely. 
Fig. 1. Effects of calcium channel blockers and quinidine on 
ATPase activity of P-glycoprotein. (A) Plasma membranes, (B) 
Purified reconstituted Pgp. O, quinidine; A, verapamil; O, 
nifedipine; zx, diltiazem. Each data point represents the mean of 
at least hree xperiments, +_SEM. 100% activity in each case 
refers to ATPase measured with no drug addition. 
3.3. Modulation of Pgp ATPase activity by cardiac 
glycosides 
Cardioactive steroids and glycosides displayed re- 
markably diverse effects on Pgp, and as Fig. 2(A) 
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Fig. 3. Dependence of ATPase activity of P-glycoprotein on MgATP concentration i  the presence and absence of digitoxin. (A) Plasma 
membranes, (B) Purified reconstituted Pgp. Km(MgATP) and Vm~ x values were determined by fitting data to the Michaelis-Menten 
equation as described in Section 2. O, no digitoxin; O, 10 txM digitoxin; ~, 30 IxM digitoxin. Each data point represents he mean of at 
least three experiments, which shared excellent agreement. 
and (B) show, the effects were seen consistently in 
both plasma membranes and pure reconstituted Pgp. 
Both the aglycone digitoxigenin and the glycoside 
digoxin stimulated Pgp ATPase activity in a concen- 
tration-dependent manner. Digoxigenin and ouabain 
had neither stimulatory nor inhibitory effect, while 
digitoxin inhibited ATPase activity. These data estab- 
lished that cardiac glycosides interact directly with 
Pgp. 
We examined whether cardiac glycosides affected 
Km(MgATP) by measuring ATPase activity as a 
function of MgATP concentration in presence and 
absence of fixed concentrations of digitoxin. The data 
are shown in Fig. 3(A) and (B), and the calculated 
K~(MgATP) and Vma x values from nonlinear least 
squares fits to the Michaelis-Menten equation are 
given in Table 1, upper half. In both plasma mem- 
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Fig. 4. Verapamil-stimulation of P-glycoprotein ATPase activity measured in the presence of digitoxin. (A) Plasma membranes, (B) 
Purified reconstituted Pgp. Km(verapamil) , Ki(digitoxin) and Vm~ , values were determined by fitting data to the Michaelis-Menten 
equation as described in Section 2 and are given in Table 1. O, no digitoxin; O, 3 IxM digitoxin; v ,  10 txM digitoxin. Each data point 
represents he mean of at least three experiments, which shared excellent agreement. 
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30 IxM digitoxin, but apparent Km(MgATP) was es- 
sentially unchanged. These data indicated that digi- 
toxin did not interfere with binding of MgATP. A 
similar set of experiments with digitoxigenin yielded 
the same conclusion (data not shown). It seemed 
likely, therefore, that the cardiac glycosides were 
acting by binding to the drug-binding site(s) in the 
Pgp membrane domains. This was examined by as- 
saying ATPase activity in presence of concentrations 
of verapamil which were shown to stimulate Pgp 
with zero, 3 or 10 IxM digitoxin also present. The 
data are shown in Fig. 4(A) and (B). Fitting these 
data by nonlinear least squares regression analysis, 
assuming simple Michaelis-Menten kinetics, revealed 
that the apparent Km(verapamil) was 0.33 IxM in 
plasma membranes and 0.4 ~M in purified reconsti- 
tuted Pgp (Table 1, lower half). In presence of digi- 
toxin, apparent Km(verapamil) was increased but no 
major changes in Vma X values occurred, suggesting 
that digitoxin competes for binding with verapamil. 
K~(digitoxin) was calculated to be 3.5 IxM in both 
plasma membranes and purified reconstituted Pgp. 
Our results uggest strongly that cardiac glycosides 
interact with Pgp directly at the site(s) which binds 
verapamil, and provide quantitative assessment of the 
apparent affinity of the interaction. Results obtained 
were similar in both plasma membrane and purified, 
reconstituted Pgp. 
3.4. Effects of tamoxifen, progesterone and naloxone 
on Pgp ATPase activi~ 
We compared the effects of the anti-estrogen a ti- 
cancer drug tamoxifen, the morphine antagonist 
naloxone, and the natural steroid progesterone, on 
Pgp in plasma membranes (Fig. 5(A)) and purified, 
reconstituted form (Fig. 5(B)). All three compounds 
stimulated ATPase activity in both systems. Proges- 
terone showed maximal stimulation at the relatively 
high concentration of 100 txM, naloxone stimulated 
only at very high concentrations (> 100 IxM). Re- 
sults with tamoxifen were dependent upon the Pgp 
preparation. In plasma membranes, tamoxifen stimu- 
lated at lower ( ~ 10 txM) concentration a d inhibited 
at higher (> 30 IxM) concentration. With pure Pgp, 
degree of stimulation was greater, but occurred at 
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Fig. 5. Effects of tamoxifen, progesterone and naloxone on 
P-glycoprotein ATPase activity. (A) Plasma membranes, (B) 
Purified reconstituted Pgp. C), tamoxifen; Q, progesterone; z~, 
naloxone. Each data point represents the mean of at least three 
experiments, +_ SEM. 100% activity in each case refers to 
ATPase measured with no drug addition. 
vious results seen with plasma membranes and indi- 
cate that each of these drugs does interact with Pgp 
directly. 
4. Discussion 
The goal of this study was to demonstrate and 
characterize the interaction of a number of drugs with 
membrane-bound and pure Pgp, using a sensitive in 
vitro ATPase assay. Two types of experimental mate- 
rial were used, namely plasma membranes i olated 
from the CR1R12 Chinese hamster ovary cell line, 
which constitutively overexpresses Pgp, and purified 
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Pgp reconstituted in liposomes using a lipid mixture 
similar to that of mammalian plasma membranes. 
Small amounts of material were sufficient for assays, 
and the use of purified Pgp suggests that effects seen 
are due to direct interaction of the drugs with Pgp. In 
Figs. 1-4 and Table 1 we established that a series of 
drugs used to treat cardiovascular disease, along with 
several other structurally and pharmacologically rele- 
vant drugs (Fig. 5) interact at the level Pgp, and we 
characterized their kinetic interaction. These kinetic 
parameters were used to provide indirect evidence of 
Pgp's apparent affinity for each of these drugs. The 
two Pgp preparations described here are shown to be 
well-suited for this purpose, and this is the first report 
of such application of purified Pgp. To confirm that 
these apparent affinities represent direct binding of 
substrate to Pgp would require employing equilib- 
rium binding assays. 
Binding of transport substrates or modulators by 
Pgp is known to be remarkably permissive, with a 
wide range of cationic or uncharged molecules, of 
diverse structure, being effective [8,9]. Subtle changes 
in structure may have dramatic effects on substrate 
efficacy, as was indicated in this work for a series of 
related digitalis analogs (Fig. 2). Previous compar- 
isons of structural features of cardiac glycosides 
[33,34], and progesterone have not revealed molecu- 
lar characteristics that correlate with observed effects 
on Pgp ATPase activity. The presence of the sugar 
moiety (Fig. 6) did not seem to be essential, as 
digitoxigenin and progesterone, which lack the rham- 
nose or digitose sugar at position C3, both stimulated 
Pgp. Likewise, the presence and position of a lactone 
ring at C 17 may not be directly related to Pgp action. 
The degree of lipophilicity and hydroxylation of the 
steroid body did correlate with efficacy, with proges- 
terone and digitoxin being most lipophilic and least 
hydroxylated, while ouabain and digitoxigenin are the 
most water soluble. In our view, the conclusion to be 
drawn is that, currently, empirical determination is 
required of whether, and in what manner, a drug 
interacts with Pgp. 
Adverse drug reactions due to intoxication by car- 
diac glycosides have long been recognized [15]. In- 
creased digoxin plasma concentrations and reduced 
digoxin excretion have been observed in patients 
upon coadministration of verapamil, diltiazem, 
nifedipine, or quinidine [ 15]. Therapeutic plasma con- 
DigRoxigenin 
" Digoxigenln 
~ - v ,~v  Olgltoxln 
C~,X.,O, 
0/~, ~ OH 
I c~,,o,  Digoxin 
1 Logo 
o,JV ~ OH 




Fig. 6. Molecular structures of digitalis analogs and progesterone. 
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centrations of quinidine, verapamil, diltiazem, and 
nifedipine are typically 10p~M [35], 0.5p~M [36], 
0.3~M [37], and 0.1p~M [38], respectively. For 
quinidine and verapamil, these values are higher than, 
or similar to, the concentrations required for half- 
maximal saturation of Pgp (Figs. 1 and 4, Table 1). 
For diltiazem and nifedipine, these values are below 
the concentration required for half-maximal satura- 
tion of Pgp. Therapeutic plasma concentrations for 
digoxin and digitoxin are < 3.5 and 38 nM, respec- 
tively [39], values which are well below the apparent 
K i or K m values toward Pgp (Fig. 2, Table 1). 
Moreover, it was indicated that digoxin and vera- 
pamil competed for binding to Pgp (Fig. 4, Table 1). 
Thus the simultaneous affects of more than one drug 
in vivo at the level of Pgp, i.e., drug-drug interac- 
tions, are to be predicted from the quantitative param- 
eters determined here, notably for verapamil and 
quinidine with digoxin or digitoxin. 
Pgp is localized in luminal brush border membrane 
of kidney proximal tubule [ 10-12,40]. Firm evidence 
for active secretion of digoxin by net vectoral trans- 
epithelial transport has come from reports using kid- 
ney epithelial cells [14,16,41-43]. Several of these 
show interference in this process by verapamil or 
quinidine, and point to failure to excrete digoxin as 
one likely mode of digoxin toxicity. It has also been 
shown that excretion of digoxin via Pgp in intestinal 
mucosa is a substantial route in mice [44]. The use of 
genetically-engineered mice, in which one of the 
genes encoding Pgp is disrupted, has clearly empha- 
sized the role of Pgp in elimination and prevention of 
tissue accumulation of digoxin. After administration 
of digoxin, elimination was notably slower in the 
"knockout" mice, leading to increased levels in 
plasma, marked accumulation i many tissues, and a 
truly striking accumulation i brain [13,14,44]. As the 
authors note, this points to possible increased risk of 
CNS toxicity in patients exposed to co-administration 
of Pgp modulators with digoxin. 
Previously, morphine and other opiate agonists 
have been characterized as Pgp substrates. They were 
shown to bind specifically to plasma membranes 
from MDR cells, and binding was inhibited by vera- 
pamil and vinblastine in concentration-dependent 
manner. Naloxone, an opiate antagonist, partly inhib- 
ited vinblastine binding at concentrations of 100 IxM 
[45]. Our results (Fig. 5) showed that naloxone, at 
concentrations of 100 p~M and above, stimulated AT- 
Pase activity in both plasma membranes and pure 
Pgp, suggesting that it interacts directly with Pgp, 
albeit with low affinity. 
Both tamoxifen and progesterone have been shown 
previously to be modulators of Pgp in cells and to 
stimulate Pgp ATPase activity in plasma membranes 
[21,46]. Data presented here confirm this work, and 
extend it to establish a direct effect also on purified 
reconstituted Pgp. Progesterone showed the same 
concentration dependence for biphasic stimulation and 
then inhibition of ATPase in both plasma membranes 
and purified reconstituted Pgp (Fig. 5). However, the 
concentration-dependence of the response to tamox- 
ifen was different in the two preparations. The most 
likely explanation is that stimulation of ATPase activ- 
ity by tamoxifen is particularly sensitive to the lipid 
environment of Pgp, which is known to affect drug- 
stimulation of Pgp ATPase activity [47]. Thus modu- 
lation of Pgp by tamoxifen in vivo may show tissue- 
specific characteristics. 
In summary, plasma membranes from a highly 
MDR cell line, and purified reconstituted Pgp, pro- 
vided a sensitive in vitro enzymic assay system for 
quantitative characterization of interaction of trans- 
port substrates and modulators with Pgp. The results 
demonstrated drug-drug interactions at the level of 
Pgp, enabling prediction of adverse reactions. Data 
with a group of widely-used cardiovascular drugs 
provide a good example of the usefulness of the 
approach. 
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